New Johnson & Johnson data show high booster shot effectiveness

Data from a phase III trial demonstrate a 94-percent protection against Covid-19 with a Johnson & Johnson booster shot.

Photo: Jens Dresling

An additional dose of Johnson & Johnson's Covid-19 vaccine has shown an effectiveness of 94 percent, the company just announced in the published results of a phase III trial.

The vaccine from Johnson & Johnson, which was previously a part of the Danish vaccination program, has demonstrated a single-dose vaccine efficacy of 70 percent.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs